Our Company
Yayo Biotech was established by returnee scientist and domestic experts in the fields of medicine and pharmacology,situated in the Pharmaceutical Valley of the Jiangbei New District in Nanjing, Jiangsu.our company is a comprehensive enterprise engaged in pharmaceutical research, development, and manufacturing. In 2020, we were recognized as a key project and facilitated our introduction into the Pharmaceutical Valley in Jiangbei New District of Nanjing.
Our company maintains a robust organizational structure and a stringent quality management system. We have developed a comprehensive documentation system that allows for effective quality control throughout the entire lifecycle of our pharmaceutical products. On June 25, 2022, we were granted the Pharmaceutical Production License by the Jiangsu Provincial Drug Administration.
We possess strong capabilities for ongoing development and innovation. Supported by our research outcomes and collaborative funding, we have been recognized as a national technology-based small and medium enterprise and have applied for status as a national high-tech enterprise. Our focus is on the research and development of targeted therapeutic agents. Currently, we have multiple innovative drugs in the pipeline, and we hold patents in several jurisdictions, including China, the United States, the European Union, and Japan.In mid-2024, the company will concurrently submit the Investigational New Drug (IND) application for its first innovative drug in both China and the United States. Phase I clinical trials were initiated in mid-2025, with Phase II trials scheduled to commence within two years of completing Phase I, while the development of a second innovative drug proceeds simultaneously.
Our History
-
Completion of Phase I clinical trials for YY2201 tablets and preparation for Phase II;
Development of a second innovative drug candidate, initiating pharmaceutical studies and non-clinical research preparations
-
On December 11, the Calcium Gluconate and Sodium Chloride Injection received marketing approval.
In July, the registration and marketing authorization application for the domestically produced Peramivir and Sodium Chloride Injection was accepted; the first subject was officially enrolled in the clinical trial for the company's first Class I innovative drug. -
September-October: Obtaining IND clinical approvals from both Chinese and US regulatory authorities；
First half: Submission of Marketing Authorization Applications (MAAs) in China for Glycerol Fructose Sodium Chloride Injection and Calcium Gluconate Sodium Chloride Injection
-
Completion of pharmaceutical studies and majority of non-clinical studies for the innovative drug YY2201
-
Acquired the Pharmaceutical Production License
-
Be recognized as a key project and integrated into the Pharmaceutical Valley
-
Completed our initial round of financing
Corporate
Culture
Core Values
Excellence: Being our Best
Innovation: Continuously innovate
Customer-focused: Prioritize customers
Quality-centric: place quality first
Our Mission
Aim to be a leader in innovative drug development, advance new pharmaceutical technologies, and deliver enhanced products and solutions for global health improvement.
